Anti-Cytochrome P450 3A4 antibody [EPR6202] (ab124921)

Overview

  • Product nameAnti-Cytochrome P450 3A4 antibody [EPR6202]
    See all Cytochrome P450 3A4 primary antibodies
  • Description
    Rabbit monoclonal [EPR6202] to Cytochrome P450 3A4
  • Tested applicationsSuitable for: WB, IP, IHC-Pmore details
    Unsuitable for: ICC/IF
  • Species reactivity
    Reacts with: Human
    Does not react with: Mouse, Rat
  • Immunogen

    Synthetic peptide corresponding to residues at the C terminus of Human Cytochrome P450 3A4.

  • Positive control
    • Human fetal liver lysate; Human liver tissue
  • General notes

    This product is a recombinant rabbit monoclonal antibody.

    Produced using Abcam’s RabMAb® technology. RabMAb® technology is covered by the following U.S. Patents, No. 5,675,063 and/or 7,429,487.

Properties

Applications

Our Abpromise guarantee covers the use of ab124921 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/10000 - 1/50000. Predicted molecular weight: 57 kDa.
IP 1/10 - 1/100.
IHC-P 1/100 - 1/250. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
  • Application notesIs unsuitable for ICC/IF.
  • Target

    • FunctionCytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. The enzyme also hydroxylates etoposide.
    • Tissue specificityExpressed in prostate and liver. According to some authors, it is not expressed in brain (PubMed:19094056). According to others, weak levels of expression are measured in some brain locations (PubMed:19359404 and PubMed:18545703). Also expressed in epithelium of the small intestine and large intestine, bile duct, nasal mucosa, kidney, adrenal cortex, epithelium of the gastric mucosa with intestinal metaplasia, gallbladder, intercalated ducts of the pancreas, chief cells of the parathyroid and the corpus luteum of the ovary (at protein level).
    • Sequence similaritiesBelongs to the cytochrome P450 family.
    • Post-translational
      modifications
      Polyubiquitinated in the presence of AMFR and UBE2G1 and also STUB1/CHIP and UBE2D1 (in vitro).
    • Cellular localizationEndoplasmic reticulum membrane. Microsome membrane.
    • Information by UniProt
    • Database links
    • Alternative names
      • 1,8-cineole 2-exo-monooxygenase antibody
      • Albendazole monooxygenase antibody
      • Albendazole sulfoxidase antibody
      • CP33 antibody
      • CP34 antibody
      • CP3A4_HUMAN antibody
      • CYP3 antibody
      • CYP3A antibody
      • CYP3A3 antibody
      • CYP3A4 antibody
      • CYPIIIA3 antibody
      • CYPIIIA4 antibody
      • Cytochrome P450 3A3 antibody
      • Cytochrome P450 3A4 antibody
      • Cytochrome P450 family 3 subfamily A polypeptide 4 antibody
      • Cytochrome P450 HLp antibody
      • Cytochrome P450 NF-25 antibody
      • Cytochrome P450 subfamily IIIA polypeptide 4 antibody
      • cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 3 antibody
      • cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 4 antibody
      • Cytochrome P450-PCN1 antibody
      • Glucocorticoid inducible P450 antibody
      • HLP antibody
      • MGC126680 antibody
      • NF 25 antibody
      • NF25 antibody
      • Nifedipine oxidase antibody
      • P450 III steroid inducible antibody
      • P450 PCN1 antibody
      • P450, family III antibody
      • P450C3 antibody
      • P450PCN1 antibody
      • Quinine 3 monooxygenase antibody
      • Quinine 3-monooxygenase antibody
      • Taurochenodeoxycholate 6 alpha hydroxylase antibody
      • Taurochenodeoxycholate 6-alpha-hydroxylase antibody
      see all

    Anti-Cytochrome P450 3A4 antibody [EPR6202] images


    • Developed using the ECL technique

      Performed under reducing conditions.

      Predicted band size : 57 kDa


      Exposure time : 20 minutes

      HepG2 cells were incubated at 37°C for 48h with vehicle control (0 μM) and different concentrations of nicardipine hydrochloride (ab120531) in DMSO. Increased expression of cytochrome P450 3A4 (ab124921) correlates with an increase in nicardipine hydrochloride concentration, as described in literature.

      Whole cell lysates were prepared with RIPA buffer (containing protease inhibitors and sodium orthovanadate), 10μg of each were loaded on the gel and the WB was run under reducing conditions. After transfer the membrane was blocked for an hour using 5% BSA before being incubated with ab124921 at 1/10000 dilution and ab9484 at 1 μg /ml overnight at 4°C. Antibody binding was detected using an anti-rabbit antibody conjugated to HRP (ab97051) at 1/10000 dilution and visualised using ECL development solution.

    • Anti-Cytochrome P450 3A4 antibody [EPR6202] (ab124921) at 1/10000 dilution + Human fetal liver lysate at 10 µg

      Secondary
      HRP labelled goat anti rabbit at 1/2000 dilution

      Predicted band size : 57 kDa
    • ab124921, at a 1/100 dilution, staining Cytochrome P450 3A4 in paraffin embedded Human liver tissue by Immunohistochemistry.
    • Equilibrium disassociation constant (KD)
      Learn more about KD

      Click here to learn more about KD

    References for Anti-Cytochrome P450 3A4 antibody [EPR6202] (ab124921)

    ab124921 has not yet been referenced specifically in any publications.

    Product Wall

    There are currently no Abreviews or Questions for ab124921.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"